Multidisciplinary Approaches Shape Treatment Pathways in EGFR-Mutated NSCLC
Emerging data in the neoadjuvant setting and the expansion of testing in standard practice have presented questions surrounding screening for and developing strategies from variant information in EGFR-mutated resectable non–small cell lung cancer.